Ingenium Research Group, Universidad de Castilla-La Mancha Ciudad Real, Edificio Politécnica 13071, Spain [email protected]

Renewable energy is being one of the options to cover the demand due to the environmental restrictions. One of the most relevant renewable energy sources is the solar energy, where the concentrated solar power is nowadays the source that is getting more importance. The correct performance of solar receiver is crucial because its failure can result in significant costs and availability of the energy service. Non-destructive testing is broadly used in structural health monitoring systems in order to detect and diagnose faults/failures. The aim of this paper is to present a fault detection and diagnosis approach based on long range ultrasonic technology, together with novel analytical procedures on signal processing of high frequency waves (Lamb waves). These waves flow through the material via the piezoelectric transducers, where these transducers are also employed as sensors. The fault can be detected and diagnosed by changes in the signal when it is modified by the fault. The experimental platform consists of: i) a data logger able to generate and read voltage signals at high frequency; ii) a sensing system based on piezoelectric transducers placed at the solar collector. A novel method of analyzing the data generated in the platform by means of time series is employed

Demonstrating public value to funders and other stakeholders—the journey of ELIXIR, a virtual and distributed research infrastructure for life science data

Open Science is a founding principle of ELIXIR, a pan-European research infrastructure for life science data, with 21 Member countries plus the European Molecular Biology Laboratory. The mission of ELIXIR is to coordinate bioinformatics resources so that they form a single, integrated and pan-European infrastructure, which can be used freely by academic and private-sector researchers across the globe. As a recipient of public and charitable funding, ELIXIR must demonstrate its value, and the need to produce evidence in support of this is intensifying. Our practice-led journey towards demonstrating public value is articulated around five main challenges and, for each, we present our pragmatic approach for tackling it. We begin by showing how we are working towards demystifying what research infrastructures do. We then shed light on the sort of evidence our funders and other stakeholders are asking us for, how this evidence varies in nature and scope, and our tactics to satisfy them. We follow-on by providing our thoughts on possible barriers and solutions to embedding impact evaluation in our activities. Finally, we provide lessons learned, which we believe are sufficiently transferable and will be inspirational to other research infrastructures as they embark on their own journeys to demonstrate public value.publishedVersio

Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

Purpose: To evaluate the safety and efficacy of selective internal radiation therapy (SIRT) in combination with a PD-1 inhibitor in patients with unresectable hepatocellular carcinoma (uHCC) and liver-only disease ineligible for chemoembolization. Patients and methods: NASIR-HCC is a single-arm, multicenter, open-label, phase 2 trial that recruited from 2017 to 2019 patients who were naïve to immunotherapy and had tumors in the BCLC B2 substage (single or multiple tumors beyond the up-to-7 rule), or unilobar tumors with segmental or lobar portal vein invasion (PVI); no extrahepatic spread; and preserved liver function. Patients received SIRT followed 3 weeks later by nivolumab (240 mg every 2 weeks) for up to 24 doses or until disease progression or unacceptable toxicity. Safety was the primary endpoint. Secondary objectives included objective response rate (ORR), time to progression (TTP), and overall survival (OS). Results: 42 patients received SIRT (31 BCLC-B2, 11 with PVI) and were followed for a median of 22.2 months. 27 patients discontinued and 1 never received Nivolumab. 41 patients had any-grade adverse events (AE) and 21 had serious AEs (SAE). Treatment-related AEs and SAEs grade 3-4 occurred in 8 and 5 patients, respectively. Using RECIST 1.1 criteria, ORR reported by investigators was 41.5% (95% CI 26.3% to 57.9%). Four patients were downstaged to partial hepatectomy. Median TTP was 8.8 months (95% CI 7.0 to 10.5) and median OS was 20.9 months (95% CI 17.7 to 24.1). Conclusions: The combination of SIRT and nivolumab has shown an acceptable safety profile and signs of antitumor activity in the treatment of patients with uHCC that were fit for SIRT

Legislación y paisaje. Un debate abierto en México

282 páginas.El libro que se vierte en las siguientes páginas supone un posible punto de conexión entre el mundo de los juristas y el de los legisladores que construyen las leyes con el de los expertos y estudiosos del paisaje. Se pretende que mediante la revisión de las contribuciones que más adelante se reseñan, el lector encuentre la oportunidad de atisbar las posibilidades y limitaciones presentes en esta discusión